GlobeNewswire by notified

Verisk Named One of UK’s Best Workplaces™ and Best Workplaces for Wellbeing™ by Great Place to Work®

Share

LONDON, April 28, 2022 (GLOBE NEWSWIRE) -- Leading global data analytics provider Verisk (Nasdaq: VRSK) has been recognised as one of the UK’s Best Workplaces™ and UK’s Best Workplaces™ for Wellbeing by Great Place to Work®, the global authority on workplace culture. Based on employee feedback, each recognition honours Verisk for creating an environment of trust, pride and camaraderie.

To determine the 2022 UK's Best Workplaces™ list, Great Place to Work® performed rigorous evaluations of hundreds of employee survey responses alongside Culture Audit™ submissions from leaders at each company. They then used the data to benchmark the effectiveness of companies' employee value propositions against the culture their employees actually experience. Businesses that achieve the highest scores after evaluation receive Best Workplaces™ status.

“We hold a deep belief in the power of bringing your whole self to work,” said Sunita Holzer, Verisk’s Chief Human Relations Officer. “Our colleagues bring out the very best in one another and strive to do better each day, which is reflected in the work to drive our customers’ businesses forward. Seeing the impact across the industries we serve empowers our team to embrace challenges and redefine what’s possible.”

As part of the evaluation for the UK's Best Workplaces™ for Wellbeing list, Great Place to Work’s culture experts assessed people’s holistic experiences of wellbeing at work by asking employees to comment on how their company supports their work-life balance, sense of fulfilment, job satisfaction, psychological safety and financial security. Evaluations also included an assessment of how well the organisation was able to deliver consistency of their employee experience across all departments and seniority levels.

Verisk is committed to fostering an inclusive, respectful environment that encourages meaningful dialogue and collaboration. Verisk empowers customers to make informed decisions, strengthen operating efficiencies and better understand global issues. Through advanced data analytics, software and deep industry knowledge, team members help others see new possibilities, inspire change and transform industries.

“Being better for people is better for business, especially in tough times,” explained Benedict Gautrey, Managing Director of Great Place to Work® UK. “When employees feel genuinely cared for, their loyalty, engagement and productivity improve. Happier people also become brand advocates for the business and will often go the extra mile to provide a positive experience for their clients and customers. Hopefully this recognition and acknowledgement will inspire more workplaces to do the same in years to come.”

Verisk has earned the Great Place to Work certification in the United Kingdom, Spain and India for two consecutive years, as well as in the United States for six years. Verisk has also been recognized by Great Place to Work UK as a Best Workplace for Women and Best Workplace in Tech and on the Spain’s Best Workplaces and Malaga’s Best Workplaces lists. In addition, Verisk was named one of the 2021 Best Workplaces in New York by Fortune magazine and Great Place to Work.

# # #

About Verisk 
Verisk (Nasdaq: VRSK) provides data-driven analytic insights and solutions for the insurance and energy industries. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk empowers customers to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global issues, including climate change and extreme events as well as political and ESG topics. With offices in more than 30 countries, Verisk consistently earns certification by Great Place to Work and fosters an inclusive culture where all team members feel they belong. For more, visit Verisk.com and the Verisk Newsroom.

About Great Place to Work®
Great Place to Work is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust. In 2022, they launched the first-ever annual UK’s Best Workplaces™ for Wellbeing list of organisations who stood out as delivering exceptional wellbeing support for their employees across all levels and departments. For more information, visit www.greatplacetowork.co.uk

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ERYTECH to Present at the H.C. Wainwright Global Investment Conference17.5.2022 22:05:00 CEST | Press release

ERYTECHtoPresent at the H.C. WainwrightGlobal Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA. The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards. Mr. Beyen will be available for one-to-one meetings with investors on May 24, 25 and 26. If you would like to arrange a one-on-one meeting or register, please contact your conference representative. For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference websi

EVS COMMUNICATES THE RESULTS OF THE ORDINARY GENERAL MEETING17.5.2022 21:59:34 CEST | Press release

Publication on May17, 2022, after market closure Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVSCOMMUNICATES THERESULTSOFTHEORDINARYGENERAL MEETING EVS Broadcast Equipment SA, leading provider of live video production systems, held its Ordinary General Meeting on May 17, 2022. In total 73 shareholders representing 2,799,870 shares, or 19.5% of the company shares, attended by proxy the Ordinary General Meeting held physically at the company's registered office but for which the company had recommended its shareholders to attend by videoconference given the still sensitive health situation. All the resolutions have been approved, i.e.: - The remuneration report, the updated remuneration policy, the discharge of the Directors and the Auditor; - The 2021 annual accounts and the allocation of profits, including a total gross dividend of EUR 1.50 for fiscal year 2021 (such dividend is made up, on the one hand, of the i

SeaLegacy Celebrates the Inaugural Year of The Good Ocean17.5.2022 21:49:59 CEST | Press release

A unified, passionate group of businesses investing in SeaLegacy’s mission to protect the world’s oceans British Columbia, Canada, May 17, 2022 (GLOBE NEWSWIRE) -- When eight companies mostly unknown to one another came together for the first time in May of 2021, they were bound only by a commitment to protect our oceans and planet. Today, these founding members of The Good Ocean are actively supporting SeaLegacy’s commitment to ocean protection. "One of the questions I get asked the most is, 'What can I do?'" says SeaLegacy Co-Founder and President Cristina Mittermeier. "This question comes from individuals, and it also comes from businesses. Increasingly, consumers are demanding the products and services they support with their purchasing power be aligned with their desire to be accountable for their impact on earth. Members of The Good Ocean are addressing that demand and stepping into the crucial role businesses play in conservation work. Together, we are taking steps towards syste

Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Press release

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition of Atrin Pharmaceuticals’ portfolio of candidate drugs, Aprea Therapeutics intends to shift its primary focus to the development of ATRN-119, a drug candidate that inhibits an important signaling pathway in DNA damage repair. ATRN-119 will soon be evaluated in clinical phase 1/2a studies in the treatment of malignant solid tumors, both as monotherapy and in combination with standard treatment. In parallel with the development of ATRN-119, separate programs are run with a second-generation ATR i

Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har förvärvat det privatägda amerikanska bioteknikbolaget Atrin Pharmaceuticals Inc. Aprea Therapeutics kommer nu att prioritera utvecklingen av Atrin Pharmaceuticals läkemedelskandidater, vilka utvecklas för att bekämpa cancersjukdomar genom att påverka de proteiner som är involverade i tumörers förmåga att reparera skador i sitt DNA. Efter förvärvet av Atrin Pharmaceuticals läkemedelsprojekt flyttar Aprea Therapeutics sitt primära fokus till utvecklingen av ATRN-119, en läkemedelskandidat som hämmar en viktig signaleringsväg vid reparation av DNA-skador. ATRN-119 kommer inom kort att börja studeras i kliniska fas 1/2a-studier vid behandling av maligna solida tumörer, både som monoterapi och i kombination med standardbehandling. Parallellt med utvecklingen av ATRN-119 bedrivs separata program med en andra generationens ATR-hämmare, ATRN-354, med poten